IBM wants to protect our food by sequencing its supply chains

[company]IBM[/company] is teaming up with food conglomerate Mars to study, and hopefully protect, citizens from foodborne illnesses by sequencing the genes of the tiny organisms that populate our food chains. Consisting of just the two companies right now but expected to grow, the effort is being called, aptly, the Consortium for Sequencing the Food Supply Chain.

The companies will study the metagenomics — essentially, the metadata — of safe factories, farms, grocery stores and other areas in order to determine what’s normal, explained Jeff Wesler, the vice president and lab director IBM’s Almaden research center in San Jose, California. Eventually, the goal is to understand enough about normal, safe conditions that companies will be able to detect deviations early enough to prevent them from spurring an outbreak of salmonella, E. coli, or other dangerous bacteria or chemicals.

For example, he explained, although many places along the food supply chain know to test for salmonella, they might not know to test for, or have any reason to expect, contamination by other substances. Those could be anything from other, foreign bacteria to chemicals such as the melamine found in Chinese milk and infant formula in 2008. Understanding the metagenomics of the product being sold and the factories producing it means companies and regulatory agencies might be able to spot a problem in the microbial ecosystem and then get to work determining what’s causing it.

According to the Centers for Disease Control, foodborne illnesses sicken one in six Americans each year and kill about 3,000 people in the United States. A 2012 study published in the Journal of Food Prediction estimates the annual economic impact of of foodborne illness at nearly $78 billion.

Analytics Process_blue background

Right now, Wesler predicts it will be about three to five years before the results of this research might be deployed commercially. The companies will spend the first couple years getting to know the baselines microbiomes of various areas and things, understanding what they’re composed of and how they react to changes in environments or to other stuff. Initial research will focus on Mars facilities, which span a range of products including candy, pet food, packaged food and coffee.

Hopefully, they’ll be able to build up a database of connections between bacteria, chemicals, heavy metals and other substances, and their reactions in the presence of each other. After that, Wesler thinks they’ll be able to begin working on a set of tests that makes sense for particular industries and that can be implemented in a reasonably easy manner.

Wesler calls this the “quintessential big data problem” because it involves analyzing so much data and is only really possible to solve now because of advances in the required technology. In this case, that’s not just cheap data storage and new data-analysis tools, but also better genetic-sequencing technologies. “One of the reasons we even think this is feasible is because of the rise of next-generation sequencing,” he said.

A major uptick in the capabilities of any piece of the chain could speed up the research, he said, but the current state of the art should be capable to work within the predicted time frame.

AncestryDNA is pushing past Hadoop as it pinpoints our pasts

AncestryDNA is getting much better at telling users where their ancestors hail from and who their relatives are, but all this improvement comes at a technological cost. The more data it gathers, the more it pushes its infrastructure and algorithms to the limit.

Omicia raises $6.8M for service that lets doctors analyze genomes for free

An Oakland-based startup called Omicia has raised a $6.8 million series A round of venture capital, led by Artis Ventures, for a cloud service that lets doctors analyze whole human genomes in order to identify the presence of diseases. The basic service is free (while more-advanced analyses and capabilities cost $99), and the whole process takes less than 3 hours for a whole genome (or less than 1 hour for an exome). Advances in sequencing, algorithms, data storage and cloud computing have been rapidly driving down the cost of genomic analysis over the past few years, leading to an uptick of of startup activity in the space.

Two new platforms for genomic analysis have raised $1.5M apiece

Two new platforms for storing and analyzing genomic data have raised venture capital recently, with Curoverse announcing $1.5 million in seed funding in mid-December and Tute Genomics announcing $1.5 million in seed funding on Dec. 31. Curoverse is a specialized private-cloud system, while Tute Genomics is a pure cloud service. Both are riding the waves of cheaper gene-sequencing costs, data storage and computing power, assuming it will result in a deluge of demand for genomic analysis over the next few years. They’re not alone: We’ve covered numerous startups trying to do the same thing, including DNAnexus, Bina Technologies, Spiral Genetics and Appistry.

More proof that health care loves big data

Two new research partnerships whose participants range from pharmaceutical companies to IT vendors are taking aim at improving disease treatment via data analysis. They’re targeting a handful of diseases specifically — heart disease and cancer among them — but they point toward a data-driven health care future.